TORONTO, Canada, September 18 /PRNewswire/ -- Trillium Therapeutics Inc., a privately-held biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders, announced today that it has secured CDN$12 million in new financing from its existing investors, VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund (CMDF).

SINGAPORE, September 18 /PRNewswire/ --

- First Truly Global CDN Supports Gaming Initiatives in APAC

MAIDENHEAD, England, September 18 /PRNewswire/ --

- New Study Results Further Support That Enbrel Effectively Clears Skin, Reduces the Prevalence of Depression and Anxiety and Improves Patients' Quality of Life

LONDON, September 18 /PRNewswire/ --

- 'Marketisation of the Vulnerable' to be Raised at Labour Party Conference

Changes in legal aid services, which help people keep 'a roof over their head', tackle unemployment and advise on crippling debts are to be raised at the Labour Party conference, by Unite.

Unite, the country's largest trade union, believes that legal assistance is being reduced, as a result of the introduction of fixed fees per case, for groups such as:

- those with literacy difficulties, - mental health problems, - disabilities, - asylum seekers and refugees

Under the Legal Services Commission's (LSC) new scheme, people with complex cases are finding it harder to get a legal aid solicitor, or an advice agency to take them on.

PRINCETON, New Jersey, September 18 /PRNewswire/ --

- Laureate To Add Single-Use Bioreactor (S.U.B.) To Its Portfolio Of Assets -

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it is increasing its existing manufacturing capacity by adding two Single-Use Bioreactors (S.U.B.). Acquisition of a 250L and a 1000L S.U.B. will give Laureate greater flexibility in meeting the varying needs of its clients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

SOUTHAMPTON, England, September 18 /PRNewswire/ -- Global leader in personal satellite navigation, Garmin has joined forces with travel experts the AA to produce a series of premium travel guides for your sat-nav, combining welcome inspiration and guidance with simple turn-by-turn directions.

The new guides are based on the popular AA lifestyle paperback versions and are available in seven downloadable categories, from great days out and hotels to golf courses and great pubs, either one guide at a time or as part of a super saver bundle package.

DALLAS, September 18 /PRNewswire/ --

- Icon of Chemical and Pharmaceutical Information Provides Quicker, More Efficient Access

Chemical Information Services announces the release of the SearcHelper enhancement, allowing subscribers access to its company, product name and CAS database vocabulary covering all classes of chemical and pharmaceutical raw materials. The new tool gives customers the ability to get a "view inside" the DWCP database and be able to choose the correct chemical and producing company from convenient, easy to read, drop-down lists.

TBILISI, Georgia, September 18 /PRNewswire/ -- The need to strengthen health systems so that they can quickly and flexibly respond to the rising number of challenges was on the agenda of WHO's European governing body, the WHO Regional Committee for Europe, that took place in Tbilisi, Georgia on 15-18 September.

Two of the most complex and persistent issues in public health have been addressed. Over 250 representatives of the countries in the WHO European Region were seeking ways to improve the governance of health systems, which means better fairness and greater efficiency, and to promote healthy behaviour.

PARIS, September 18 /PRNewswire/ --

- Additional Analysis Shows HUMIRA Effectively Treats Adult Patients with Moderate to Severe Psoriasis Regardless of Age, Duration of Disease, Diagnosis of Psoriatic Arthritis or Recent Systemic Therapy

More psoriasis patients achieve efficacy when they receive continuous treatment with HUMIRA(R) (adalimumab) compared to patients who interrupt their therapy, according to data presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris. The findings were from a sub-analysis of Abbott's pivotal, 52-week study, REVEAL (The Randomized Controlled EValuation of Adalimumab Every Other Week in Moderate to Severe Psoriasis Trial) and the period of open-label treatment that followed.

LEEDS, England, September 18 /PRNewswire/ -- The world-leading industrial gas supplier, Air Products, has chosen Masternaut Three X to supply a ground-breaking web-based satellite tracking solution for their UK and Ireland cylinder gas business (Packaged Gases). Following a highly successful trial of the Masternaut real-time service, the company has rolled out the solution to their delivery fleet. Masternaut will enable Air Products to optimise its route planning, reducing its carbon footprint, and provide a highly secure, fully automatic seamless lone-worker safety system.